Walking a Tightrope: Dosage Modifications and Treatment Outcomes of All-Trans-Retinoic Acid, Arsenic Trioxide, and Daunorubicin for High-Risk Acute Promyelocytic Leukemia

Walking a Tightrope: Dosage Modifications and Treatment Outcomes of All-Trans-Retinoic Acid, Arsenic Trioxide, and Daunorubicin for High-Risk Acute Promyelocytic Leukemia

PURPOSEThe use of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) in the treatment of low- and intermediate-risk acute promyelocytic leukemia (APL) is the standard of care. We report the combined use of ATRA, ATO, and daunorubicin (DNR) in patients newly diagnosed with high-risk APL. The p...

Full description

Bibliographic Details
Main Authors: Madhav Danthala, Krishna Reddy Golamari, Arun Seshachalam, Anupama Mikkilineni, Sitalata Chappidi, Mahesh Babu Mekala, Vidhubala Elangovan, Palanivel Chinnakali
Format: Article
Language:English
Published: American Society of Clinical Oncology 2020-11-01
Series:JCO Global Oncology
Online Access:https://ascopubs.org/doi/10.1200/GO.20.00226

Internet

https://ascopubs.org/doi/10.1200/GO.20.00226

Similar Items